Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;95(1):e28133.
doi: 10.1002/jmv.28133. Epub 2022 Sep 19.

SARS-CoV-2 IgG "heritage" in newborn: A credit of maternal natural infection

Laura Marchi  1 , Annalisa Vidiri  2 , Emanuele Arturo Fera  3 , Marta Pallottini  1 , Federica Perelli  4 , Monica Gardelli  1 , Tamara Brunelli  5 , Paolo Dal Poggetto  6 , Elena Martelli  6 , Gianluca Straface  7 , Fabrizio Signore  8   9 , Ismaele Fusco  5 , Pier Luigi Vasarri  6 , Giovanni Scambia  2 , Anna Franca Cavaliere  1
Affiliations

SARS-CoV-2 IgG "heritage" in newborn: A credit of maternal natural infection

Laura Marchi et al. J Med Virol. 2023 Jan.

Abstract

Description of transplacental passage of specific SARS-CoV-2 IgG from mothers who contracted natural infection to their newborns. Retrospective cohort analysis including pregnant women diagnosed with SARS-CoV-2 and their newborns both tested for SARS-CoV-2 specific IgG and IgM with antibody titration at delivery. Nasopharyngeal swab were taken from both mothers and neonates, and tested for SARS-CoV-2 using polymerase chain reaction (PCR). IgM and IgG were analyzed in maternal and neonatal serum of 143 mother-infant dyads. 86% of women with a positive SARS-CoV-2 PCR >14 days before delivery developed specific IgG and 84% of their infants showed transplacental passage of IgG. Pregnant women infected with SARS-CoV-2 achieve antibody seroconversion following the kinetics described in the general population, and transplacental transfer of IgG specific antibodies occurs. No conclusion can be drawn on passive immunity efficacy or duration.

Keywords: SARS-CoV-2; natural infection; passive immunity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Dumitriu D, Emeruwa UN, Hanft E, et al. Outcomes of neonates born to mothers with severe acute respiratory syndrome coronavirus 2 infection at a large medical center in New York City. JAMA Pediatr. 2021;175(2):157‐167. 10.1001/jamapediatrics.2020.4298 - DOI - PMC - PubMed
    1. Jeganathan K, Paul AB. Vertical transmission of SARS‐CoV‐2: a systematic review. Obstet Med. 2022;15(2):91‐98. 10.1177/1753495X211038157 - DOI - PMC - PubMed
    1. Boyce TG, Chako EM, Mascola MA. Case report: fatal COVID‐19 in a neonate after probable late intrauterine transmission. J Neonatal Perinatal Med. 2022;1‐5. 10.3233/NPM-221002 - DOI - PubMed
    1. Carosso A, Cosma S, Borella F. Pre‐labor anorectal swab for SARS‐CoV‐2 in COVID‐19 pregnant patients: is it time to think about it? Eur J Obstet Gynecol Reprod Biol. 2020;249:98‐99. 10.1016/j.ejogrb.2020.04.023 - DOI - PMC - PubMed
    1. Walker KF, O'donoghue K, Grace N, et al. Maternal transmission of SARS‐COV‐2 to the neonate, and possible routes for such transmission: a systematic review and critical analysis. BJOG. 2020;127(11):1324‐1336. 10.1111/1471-0528.16362 - DOI - PMC - PubMed